<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasma endothelin-1, the nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) mediator intraplatelet cyclic <z:chebi fb="0" ids="16750">guanosine</z:chebi> monophosphate (cGMP), the prostacyclin mediator cyclic <z:chebi fb="3" ids="16335">adenosine</z:chebi> monophosphate (cAMP) and the macrophage derived inflammatory mediator plasma neopterin were measured in men with Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (n=91), <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT; n=51), previously <z:hpo ids='HP_0001952'>abnormal glucose tolerance</z:hpo> (PAGT; n=20), and 34 healthy control men </plain></SENT>
<SENT sid="1" pm="."><plain>Plasma endothelin-1was higher in men with Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> than in controls [4.1 (1.0-14.3) vs. 2.1 (0.2-8 </plain></SENT>
<SENT sid="2" pm="."><plain>7) ng/l; P&lt;0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>Intraplatelet cGMP was higher in men with PAGT [0 </plain></SENT>
<SENT sid="4" pm="."><plain>84 (0.57-2.76) pmol/10(9) platelets; P&lt;0.05], IGT [0.85 (0.48-3.53); P&lt;0.001] and Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> [0.90 (0.47-3.86); P&lt;0.001] than in controls [0.70 (0.42-1.70] </plain></SENT>
<SENT sid="5" pm="."><plain>No differences existed between groups concerning intraplatelet cAMP or plasma neopterin </plain></SENT>
<SENT sid="6" pm="."><plain>Plasma endothelin-1 correlated with fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (r=0.33; P&lt;0.001) and HbA1(c) (r=0.29; P&lt;0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, elevated plasma endothelin-1 in Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and its relationship to <z:chebi fb="105" ids="17234">glucose</z:chebi> and HbA1(c) suggest a putative role for endothelin-1 in diabetic endothelial cell damage </plain></SENT>
<SENT sid="8" pm="."><plain>Increased cGMP indicating enhanced production/activity of NO suggests that factors other than reduced NO activity contribute to enhanced platelet aggregation in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>